Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PUR118 · 3 trials · 3 indications
Changes in clinical signs and symptoms from physical examination and chest examination, changes in clinical safety laboratory tests, vital signs, spirometry, lung clearance index, 24-hour sputum weight and volume, oxygen saturation, ECG, telemetry, and adverse events.
| Arm | Type | Description |
|---|---|---|
| PUR118 low dose | EXPERIMENTAL | - |
| PUR118 mid dose | EXPERIMENTAL | - |
| PUR118 high dose | EXPERIMENTAL | - |
| PUR118 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PUR118 | DRUG | inhaled PUR118, BID |
Inclusion Criteria: * Healthy males or non pregnant, non lactating healthy females age 18-50 years; * Must be able to produce acceptable sputum sample by induction; * Must respond to ozone inhalation with a \> 10% increase in the absolute percentage of sputum neutrophils and the total neutrophils (...
PUR118 is an investigational small molecule being developed for respiratory conditions, including Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PUR118 is being developed by Pulmatrix, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol PULM. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
PUR118 is in Phase 1 clinical development. It has completed three Phase 1 trials, including studies in healthy volunteers and patients with COPD or Cystic Fibrosis. The drug remains investigational and has not received regulatory approval.
PUR118 has completed three Phase 1 trials: NCT01333904 in COPD patients, NCT01543191 in Cystic Fibrosis patients, and NCT01690949 in healthy volunteers exposed to ozone. All trials were completed, with the COPD study enrolling 90 participants.
PUR118 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial data, so it is not known to be identical to any other marketed or investigational product.